Compare Prospect Capital Corporation (PSEC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs 22nd Century Group Inc — how do they compare? Prospect Capital Corporation trades at $2.14 (market cap $1.08B), while 22nd Century Group Inc trades at $4.15 (market cap $1.56M). The key difference: Prospect Capital Corporation is far larger — about 692.3× 22nd Century Group Inc's market cap, and Prospect Capital Corporation pays a 23.26% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| PSEC | XXII | |
|---|---|---|
Market Cap | $1.08B | $1.56M |
Sector | Financials | Technology |
52-Week High | $3.47 | $999.00 |
52-Week Low | $2.15 | $3.90 |
Dividend Yield | 23.26% | — |
Enterprise Value | — | -$6.67M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $4.32, down 0.23% on the day, with neutral technical signals and bearish moving averages. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and declining revenue, though analyst sentiment remains positive with 75% buy ratings. Recent corporate actions include a 20:1 reverse stock split completed in June 2026, while expansion initiatives in California and New York aim to drive VLN brand growth.
The outlook remains speculative with high execution risk given persistent losses and negative ROE (-130.19%). Investment opportunity hinges on successful commercialization of reduced-nicotine products and FDA regulatory progress, but substantial financial deterioration and competitive pressures present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
